The failure of vitamin K therapy against type B hemophilia and other gene-linked clotting disorders occurs because the vitamin acts by inducing clotting protein synthesis at this same level, a St. Louis University biochemist believes.
Robert E. Olson, MD, PhD, presented this hypothesis at the recent St. Louis symposium honoring the retirement of Edward A. Doisy, PhD, Nobel laureate.
The observations of Dr. Olson were doubly appropriate to the occasion. It was Dr. Doisy who shared the 1943 Nobel prize in medicine and physiology for elucidating the chemical nature of vitamin K. And, Dr. Olson recently succeeded Dr. Doisy as chairman of the St. Louis University Department of Biochemistry.
Eleven other biochemists—four fellow Nobel laureates, six former graduate students and a lifelong associate—also presented papers at Dr. Doisy's "scientific day."
The Nobel laureate participants: Prof Henrik Dam, Copenhagen, Denmark, who shared the prize with Dr. Doisy; Prof Adolf Butenandt, Munich,